Russell Zelig Szmulewitz

12PUBLICATIONS
172CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 01, 2026
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).

Santosh Gupta, Siyuan Guo, Susan Halabi

|Mar 04, 2026
131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.

Evan Y Yu, Vivek Narayan, Giuseppe Esposito

|Feb 26, 2026
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Andrew J Armstrong, Michael J Morris, Wassim Abida

|Nov 20, 2025
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.

Deaglan McHugh, Matthew Dallos, Min Yuen Teo

|Aug 12, 2025
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer.

John T Phoenix, Audris Budreika, Devin A Schmeck

|Dec 19, 2024
Differential DNA Methylation in the Benign and Cancerous Prostate Tissue of African American and European American Men.

Meytal Chernoff, Kathryn Demanelis, Marc Gillard

Pageof 2

Frequent Collaborators

4 joint publications

Andrew J Armstrong

4 joint publications

Susan Halabi

4 joint publications

Emmanuel S Antonarakis

3 joint publications

Daniel J George